

Mitochondrial myopathies treatment market is poised to grow at a CAGR of 3.2 % till 2023

Mitochondrial Myopathies Market Information: by type (Kearns-Sayre syndrome (KSS), Leigh syndrome, Mitochondrial DNA) by therapies-Global Forecast to 2023

PUNE, MAHARASHTRA, INDIA, July 10, 2017 /EINPresswire.com/ -- Market Highlights



Major Key Players are Reata Pharmaceuticals, Inc., Stealth BioTherapeutics, Raptor Pharmaceutical Corp., GeneDx, NeuroVive Pharmaceutical AB

Market Research Future

Market research future has a half cooked research report on global mitochondrial myopathies treatment market. The global mitochondrial myopathies treatment market is growing at a rate of 3.2% and is expected show the similar trend during forecast period.

Mitochondrial myopathy is an umbrella term for rare genetic diseases due to defective mitochondria in cells which results in inability of the mitochondria to consume normal levels of oxygen and produce energy. The disease manifests itself from infancy to adulthood.

Although there is no cure for the disease, there have been some research initiatives from pharmaceutical companies. For example, the drug Bendavia of Stealth BioTherapeutics Inc. is undergoing Phase 2 clinical trials and aims to reduce oxidative stress in cells. The drug targets lipids known as cardiolipin, found in the mitochondria to increase energy production.

Request a Sample Report @ https://www.marketresearchfuture.com/sample request/3684

Major Market Players:

- Reata Pharmaceuticals, Inc.,
- Stealth BioTherapeutics,
- •Raptor Pharmaceutical Corp.,
- •GeneDx.
- NeuroVive Pharmaceutical AB

Reata Pharmaceuticals has taken the approach of selectively activating cell signalling so as to increase mitochondrial biogenesis, and increase mitochondrial efficiency of energy production. Cysteamine from Raptor Pharmaceuticals is undergoing advanced Phase 3 clinical trials and is targeted to alter glutathione synthesis. The drug intends to increase the conversion of cystine into cysteine which is the critical step for glutathione synthesis. Thus by increasing the conversion of cystine into cysteine and by reducing the level of oxidative damage it will bring long tern cure for Leigh syndrome. Other research initiatives are stem cell therapies and mitochondrial DNA transfers. However these research is still in its infant developmental stage.

Current research aims to increase energy production in the form of adenosine triphosphate (ATP) or to reduce production of free radical. Another strategy is to increase critical enzymatic reactions and scavenge toxic coenzymes, which accumulate during mitochondrial disease. Research is also aiming to find alternative biological energy fuels.

Test the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on "Mitochondrial myopathies treatment Market Research Report-Forecast to 2023."

Report Details @ https://www.marketresearchfuture.com/reports/mitochondrial-myopathies-market-3684

Segmentation:

The global mitochondrial myopathies market is segmented on the basis of type and therapies. Based on type, the market has been segmented as Kearns-Sayre syndrome (KSS), Leigh syndrome, Mitochondrial DNA depletion syndrome (MDS), mitochondrial encephalomyopathy, Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), Myoclonus epilepsy with ragged red fibers (MERRF), Neuropathy, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, Progressive external ophthalmoplegia (PEO). Based on the therapies, the market has been segmented as dietary, supportive, vitamins, coenzymes and antioxidants and other.

Table of Content

- 1. Introduction
- 1.1 Definition
- 1.2 Scope Of Study
- 1.2.1 Research Objective
- 1.2.2 Assumptions & Limitations
- 1.2.2.1 Assumptions
- 1.2.2.2 Limitations
- 1.3 Market Structure:
- 2. Research Methodology
- 2.1 Research Process:
- 2.2 Primary Research
- 2.3 Secondary Research:
- Market Dynamics
- 3.1 Drivers
- 3.2 Restraints
- 3.3 Opportunities
- 3.4 Macroeconomic Indicators
- 4. Market Factor Analysis

Continued.....

Browse Related Statistical Report

<u>Europe organ transplantation cases</u>, by type of organ are projected to grow at the CAGR 0f 3.0% during the forecasted period 2016-2027. The total organ transplantation cases in Europe in 2027 are expected to reach 46,577 from 31,849 in 2015. Liver transplants cases are the fastest growing segment at the CAGR of 3.6%. On the other hand, the total organ transplantation rejection cases in Europe were 6,992 in 2015.

https://www.marketresearchfuture.com/statistical-reports/europe-organ-transplant-rejection-market-2141

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:

Name: Akash Anand

Organization: Market Research Future

Address: Market Research Future Office No. 524/528,

Phone: +1 646 845 9312

Email: akash.anand@marketresearchfuture.com

Akash Anand Market Research Future +1-646-845-9349 (US) / +44 208 133 9349 (UK) email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.